CO6400142A2 - Derivados de imidazol como antagonistas de mglur5 - Google Patents
Derivados de imidazol como antagonistas de mglur5Info
- Publication number
- CO6400142A2 CO6400142A2 CO11164352A CO11164352A CO6400142A2 CO 6400142 A2 CO6400142 A2 CO 6400142A2 CO 11164352 A CO11164352 A CO 11164352A CO 11164352 A CO11164352 A CO 11164352A CO 6400142 A2 CO6400142 A2 CO 6400142A2
- Authority
- CO
- Colombia
- Prior art keywords
- lower alkyl
- independently
- alkoxyalkyl
- hydrogen
- hydroxyalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a derivados de imidazol de la fórmula generalen dondeR1, significa halógeno, alquilo inferior ó alcoxi inferior; R2, significa aIquiIo inferior, hidroxialquilo inferior, o alcoxialquilo inferior;R3, significa hidrógeno, alquilo inferior hidroxialquilo inferior o alcoxialquilo;Q, significa ó -N= ó -CH=;R4, es un grupo de la formula IIa ó lIben donde,X, Y y Z, son, de una forma independiente, -CH= ó -N=; y en donde, solamente una de X ó Y, puede ser un átomo de nitrógeno;R5 y R6 son, de una forma independiente, hidrógeno, alquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, -(CH2)m-(CO)O-alquilo inferior, -(CH2)m-S(O)2-alquilo inferior, -(CH2)m-C(O)NR´R", y en donde, m = 0 - 3 y R' y R" son, de una forma independiente, hidrógeno ó alquilo inferior,así como a las sales farmacéuticamente aceptables de éstos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09165780 | 2009-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6400142A2 true CO6400142A2 (es) | 2012-03-15 |
Family
ID=42358156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11164352A CO6400142A2 (es) | 2009-07-17 | 2011-11-29 | Derivados de imidazol como antagonistas de mglur5 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8334287B2 (es) |
| EP (1) | EP2456765B1 (es) |
| JP (1) | JP5667182B2 (es) |
| KR (1) | KR101431347B1 (es) |
| CN (1) | CN102471309B (es) |
| AR (1) | AR077481A1 (es) |
| AU (1) | AU2010272585B2 (es) |
| BR (1) | BR112012001092A2 (es) |
| CA (1) | CA2765921C (es) |
| CL (1) | CL2012000102A1 (es) |
| CO (1) | CO6400142A2 (es) |
| CR (1) | CR20110659A (es) |
| CY (1) | CY1114186T1 (es) |
| DK (1) | DK2456765T3 (es) |
| EC (1) | ECSP12011611A (es) |
| ES (1) | ES2411467T3 (es) |
| HK (1) | HK1169397A1 (es) |
| HR (1) | HRP20130657T1 (es) |
| IL (1) | IL216746A (es) |
| MA (1) | MA33386B1 (es) |
| MX (1) | MX2012000814A (es) |
| MY (1) | MY156878A (es) |
| NZ (1) | NZ596810A (es) |
| PE (1) | PE20120397A1 (es) |
| PL (1) | PL2456765T3 (es) |
| PT (1) | PT2456765E (es) |
| RS (1) | RS52901B (es) |
| RU (1) | RU2527106C2 (es) |
| SG (1) | SG178052A1 (es) |
| SI (1) | SI2456765T1 (es) |
| TW (1) | TWI423964B (es) |
| UA (1) | UA107086C2 (es) |
| WO (1) | WO2011006910A1 (es) |
| ZA (1) | ZA201109451B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| US20170173008A1 (en) * | 2014-03-19 | 2017-06-22 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965583A (en) * | 1997-04-24 | 1999-10-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory disease |
| KR100515549B1 (ko) | 2000-12-04 | 2005-09-20 | 에프. 호프만-라 로슈 아게 | 글루타메이트 수용체 길항제로서의 페닐에테닐 또는페닐에티닐 유도체 |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| EP1670784B1 (en) * | 2003-06-12 | 2011-01-12 | F. Hoffmann-La Roche AG | Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists |
| US7452909B2 (en) * | 2003-09-04 | 2008-11-18 | Hoffman-La Roche Inc. | Imidazole derivatives |
| PL1756086T3 (pl) * | 2004-06-01 | 2008-11-28 | Hoffmann La Roche | Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5 |
| BRPI0511678A (pt) * | 2004-06-01 | 2008-01-08 | Hoffmann La Roche | piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5 |
| EP2578216A1 (en) | 2006-11-22 | 2013-04-10 | Seaside Therapeutics, Inc. | Methods of treating fragile x syndrome |
-
2010
- 2010-07-09 US US12/833,017 patent/US8334287B2/en active Active
- 2010-07-14 PT PT107301921T patent/PT2456765E/pt unknown
- 2010-07-14 CN CN201080031886.6A patent/CN102471309B/zh active Active
- 2010-07-14 SG SG2012003661A patent/SG178052A1/en unknown
- 2010-07-14 SI SI201030209T patent/SI2456765T1/sl unknown
- 2010-07-14 CA CA2765921A patent/CA2765921C/en not_active Expired - Fee Related
- 2010-07-14 RU RU2012104399/04A patent/RU2527106C2/ru not_active IP Right Cessation
- 2010-07-14 KR KR1020127004121A patent/KR101431347B1/ko active IP Right Grant
- 2010-07-14 PE PE2012000035A patent/PE20120397A1/es not_active Application Discontinuation
- 2010-07-14 AU AU2010272585A patent/AU2010272585B2/en not_active Ceased
- 2010-07-14 TW TW099123206A patent/TWI423964B/zh not_active IP Right Cessation
- 2010-07-14 UA UAA201201027A patent/UA107086C2/ru unknown
- 2010-07-14 EP EP10730192.1A patent/EP2456765B1/en active Active
- 2010-07-14 RS RS20130331A patent/RS52901B/en unknown
- 2010-07-14 DK DK10730192.1T patent/DK2456765T3/da active
- 2010-07-14 WO PCT/EP2010/060097 patent/WO2011006910A1/en active Application Filing
- 2010-07-14 MA MA34494A patent/MA33386B1/fr unknown
- 2010-07-14 BR BR112012001092-1A patent/BR112012001092A2/pt not_active Application Discontinuation
- 2010-07-14 JP JP2012520013A patent/JP5667182B2/ja active Active
- 2010-07-14 MY MYPI2012000151A patent/MY156878A/en unknown
- 2010-07-14 MX MX2012000814A patent/MX2012000814A/es active IP Right Grant
- 2010-07-14 ES ES10730192T patent/ES2411467T3/es active Active
- 2010-07-14 NZ NZ596810A patent/NZ596810A/en not_active IP Right Cessation
- 2010-07-14 PL PL10730192T patent/PL2456765T3/pl unknown
- 2010-07-15 AR ARP100102580A patent/AR077481A1/es unknown
-
2011
- 2011-11-29 CO CO11164352A patent/CO6400142A2/es active IP Right Grant
- 2011-12-01 IL IL216746A patent/IL216746A/en not_active IP Right Cessation
- 2011-12-08 CR CR20110659A patent/CR20110659A/es unknown
- 2011-12-21 ZA ZA2011/09451A patent/ZA201109451B/en unknown
-
2012
- 2012-01-13 CL CL2012000102A patent/CL2012000102A1/es unknown
- 2012-01-17 EC EC2012011611A patent/ECSP12011611A/es unknown
- 2012-10-12 HK HK12110080.6A patent/HK1169397A1/xx unknown
-
2013
- 2013-07-10 HR HRP20130657AT patent/HRP20130657T1/hr unknown
- 2013-07-22 CY CY20131100614T patent/CY1114186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
| AR086539A1 (es) | COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE | |
| PE20160115A1 (es) | Compuestos derivados de imidazol como inhibidores de protein quinasa | |
| MX2011011875A (es) | Compuesto de carboxamida heterociclica diamino. | |
| CO6140030A2 (es) | Derivados de 4-bencilftalazinona 2-sustituidos como antagonistas de histamina h1 y h3 | |
| PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
| CR11738A (es) | Compuestos de pirimidinona pirrolo 3-metil-2-imino fenil sustituidos como inhibidores bace-1, composiciones y su uso | |
| TW200745032A (en) | Novel heterobicyclic derivatives | |
| MX2010008362A (es) | Derivados de heteroarilamida diazepinopirimidona sustituidos. | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| EA201600403A1 (ru) | N-ацилиминогетероциклические соединения | |
| MX2009012380A (es) | Compuestos de heteroarilamida pirimidona. | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| MX2009009121A (es) | Aminoamidas como antagonistas de orexina. | |
| PE20100718A1 (es) | Derivados triciclicos de 1, 4-dihidropiridina [b, e]-condensados como inhibidores de aurora quinasas | |
| MX2010008360A (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos. | |
| PE20120640A1 (es) | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb) | |
| MX2010002352A (es) | Piperazinil pirazinas y piridinas substituidas como antagonistas del receptor 5-ht7. | |
| CO6400142A2 (es) | Derivados de imidazol como antagonistas de mglur5 | |
| EA201170844A1 (ru) | Ингибиторы цистеинпротеазы | |
| IN2013MN00506A (es) | ||
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |